在走向全球消灭脊髓灰质炎的旅程中重新引入OPV:低禁忌人群比例的估算
2013年以色列野生脊髓灰质炎病毒再现后恢复常规OPV接种,卫生部因担心免疫缺陷者发生VAPP而规定了接种者及家庭接触者的禁忌证。本研究基于医疗记录数据库提取的禁忌率构建统计模型,估算2-9月龄和14-23月龄接种候选者中禁忌人群规模,结果显示两个年龄组禁忌比例分别为3.9%和4%,低于卫生部预期。
要点
- 2013年以色列野生脊髓灰质炎病毒再现后恢复了常规OPV接种。
- 2-9月龄组禁忌比例为3.9%,14-23月龄组为4%。
- 统计模型可用于未来制定疫苗接种活动时估算禁忌人群。
核心结论
- 统计模型可提供禁忌人群的估算,并可用于未来制定疫苗接种活动。
- 与卫生部提出的担忧相反,本研究发现禁忌人群比预期的小。
研究设计与样本
- 研究纳入2-9月龄和14-23月龄的接种候选者及可能的家庭接触者。
- 从医疗记录数据库提取各研究组的禁忌率,并构建统计模型估算候选者发生禁忌的概率。
主要发现
- 2-9月龄研究组中3.9%存在自身或家庭接触者禁忌。
- 14-23月龄组中4%存在自身或家庭接触者禁忌。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The 2013 reemergence of wild poliovirus in Israel led to the reinstatement of a routine OPV vaccination. Fearing VAPP in immunocompromised, the MOH regulated contraindications for vaccination candidates and household contacts. In this study we estimate the size of the contraindicated population to OPV vaccination. METHOD: We studied vaccination candidates aged 2-9 and 14-23 months and probable household contacts. Using the rate of contraindications extracted for each study group from a medical records database, a statistical model was built to estimate the probability of contraindications in candidates. RESULTS: 3.9% of the 2-9-month-old study group and 4% of the 14-23-month-old group had contraindications by either self or household contacts. CONCLUSION: A statistical model can provide an estimation of the contraindicated population and can be used in the future when devising vaccination campaigns. In contrast to concerns raised by the MOH, our findings show a smaller than anticipated contraindicated population.
引用
- Rosenberg Danziger C, Anis E, Gordon ES, et al. Reintroducing OPV in Israel on the journey to global polio eradication - Estimation at a low rate of contraindicated population. Vaccine. 2018. PMID: 29776752. doi:10.1016/j.vaccine.2018.05.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。